Inhibikase Therapeutics, Inc.

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

The number of biopharmaceutical companies that have gone public in the US in 2024 has now beat the 2023 total of 21 with the 10 October initial public offerings by Upstream Bio Inc. and CAMP4 Thera

Alvotech Awaits Key FDA Inspection Alvotech is set to face a long-awaited US Food and Drug Administration reinspection of its Reykjavik facility in January, in a key milestone for the Icelandic firm

Despite recent scrutiny of US Food and Drug Administration clinical holds on investigational cell and gene therapies, the number of holds has declined in the last three years to 70 in calendar year 20